Department of Nuclear Medicine, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, 110029, India,
Jpn J Radiol. 2013 Nov;31(11):766-9. doi: 10.1007/s11604-013-0250-4. Epub 2013 Oct 2.
Pulmonary alveolar microlithiasis (PAM) is a very rare disease in which multiple microscopic calcium phosphate microliths are deposited within the alveoli of both lungs. A lung biopsy is considered to be definitive for final diagnosis; however, non-invasive imaging modalities such as chest X-ray, HRCT scan and (99m)Tc-MDP bone scan suggest the diagnosis in the vast majority of patients. Although (18)F-FDG PET/CT has been tried to characterize the disease, (18)F-sodium fluoride PET/CT as a 'proof-of-principle' was tried for the first time in a known case of PAM in order to characterize the lung lesions. Interestingly, we noted that (18)F-sodium fluoride PET/CT is a superior modality in characterization and assessment of the extent of disease in PAM compared to all other non-invasive imaging modalities. Thus, we recommend that (18)F-sodium fluoride PET/CT should be the investigation of choice in PAM.
肺肺泡微结石症(PAM)是一种非常罕见的疾病,其特征是双肺肺泡内沉积有多个显微镜下的磷酸钙微结石。肺活检被认为是最终诊断的金标准;然而,胸部 X 射线、高分辨率 CT 扫描和(99m)Tc-MDP 骨扫描等非侵入性成像方式在绝大多数患者中提示了该疾病的诊断。尽管已经尝试使用 (18)F-FDG PET/CT 来描述该疾病,但我们首次尝试使用 (18)F-氟化钠 PET/CT 作为“原理验证”,以对已知的 PAM 病例进行肺部病变的特征描述。有趣的是,我们注意到与其他非侵入性成像方式相比,(18)F-氟化钠 PET/CT 在 PAM 的特征描述和疾病程度评估方面具有优势。因此,我们建议在 PAM 中应选择 (18)F-氟化钠 PET/CT 作为首选检查方法。